Aggressive T-Cell Non-Hodgkin Lymphoma — Trials

Aggressive T-Cell Non-Hodgkin Lymphoma — Trials · CancerIndex

Clinical trials

Registered studies

289 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 62
Recruiting: 32
Ph III recruiting: 3
Growth YoY: —
Industry share: 21%
Top sponsor: City of Hope Medical Center
Termination share: 33%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (47)

clinicaltrialsPublishedShowing 51–100 of 104 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT01678443	Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies	terminated	Phase 1	2	Fred Hutchinson Cancer CenterOTHER	1	Apr 2, 2021	clinicaltrials
NCT02273739	Study of Orally Administered Enasidenib (AG-221) in Adults With Advanced Solid Tumors, Including Glioma, or Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation	completed	Phase 1 / Phase 2	21	CelgeneINDUSTRY	2	Feb 23, 2021